• Consortium formed between WACKER & CordenPharma has officially entered the pandemic readiness state as of 1 June 2024 to produ...
Moderna, announced that its Phase 3 trial of mRNA-1283, an investigational next-generation COVID-19 vaccine, has met its primary efficacy endpoint, demon...
Amidst growing concerns from U.S. federal, state and local agencies over Highly Pathogenic Avian Influenza (HPAI) A (H5N1) detections in dairy cows, Inte...
BioNTech and CEPI aim to enhance local R&D, clinical and commercial-scale manufacturing capacities to develop potential mRNA vaccines in Africa, fo...
CancerVax, Inc., the developer of breakthrough cancer drugs that will use the body’s immune system to fight cancer, announced that its UCLA res...
Moderna, Inc. received notification from the U.S. Food and Drug Administration (FDA) regarding a delay in the review process for its investigational respir...
Agreement provides patients with broader access to a protein-based non-mRNA adjuvanted COVID-19 vaccine through combined commercial strength, fro...
ArkeaBio™, a leading ag-biotech start-up developing a vaccine to reduce livestock methane emissions, announced the close of a $26.5 million Series A ...
Bavarian Nordic A/S announced the award of a contract valued at EUR 65 million to supply its MVA-BN® smallpox vaccine to the strategic reserve wi...
Game-changing continuous-batch production of RNA service removes process development and scale-up steps through automation and significantly cuts clinical ...
Croda International Plc (Croda) and The Access to Advanced Health Institute (AAHI) are pleased to announce the signing of a partnership agreement around in...
Rob Truckenmiller, Senior Vice President, Head of US Vaccines, GSK, emphasized the importance of collaborative efforts and fi...
Biological E. Limited (BE) to Manufacture Up to 50 Million Doses of QDENGA Per Year, Accelerating Takeda’s Ability to Deliver 100 Million Doses Per...
LimmaTech Biologics AG, announced encouraging interim results from its Phase I/II clinical trial evaluating Shigella4V (S4V), a promising tetravalent bioco...
© 2025 Biopharma Boardroom. All Rights Reserved.
